Literature DB >> 29904176

Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).

Erika K S M Leenders1, Harm Westdorp2,3, Roger J Brüggemann4, Jan Loeffen5,6, Christian Kratz7, John Burn8, Nicoline Hoogerbrugge1, Marjolijn C J Jongmans9,10,11.   

Abstract

Constitutional MisMatch Repair Deficiency (CMMRD) is caused by homozygous or compound heterozygous germline variants in one of the mismatch repair (MMR) genes (MSH2, MSH6, PMS2, MLH1). This syndrome results in early onset colorectal cancer, leukemia and lymphoma, brain tumors and other malignancies. Children with CMMRD are at high risk of developing multiple cancers and cancer surveillance does not guarantee detection of cancer at a curable stage. The development of a preventive treatment strategy would be a major step forward. Long-term daily use of acetylsalicylic acid (ASA) has been shown to reduce cancer risk in individuals with Lynch syndrome (LS). LS is caused by heterozygous germline variants of MSH2, MSH6, PMS2 and MLH1 and characterized by an increased risk of developing colorectal and endometrial cancer at adult age. Here we discuss the potential use of ASA for cancer prevention in patients with CMMRD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29904176      PMCID: PMC6138701          DOI: 10.1038/s41431-018-0197-0

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  57 in total

1.  Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection.

Authors:  Michael D Howell; Victor Novack; Philip Grgurich; Diane Soulliard; Lena Novack; Michael Pencina; Daniel Talmor
Journal:  Arch Intern Med       Date:  2010-05-10

2.  Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium.

Authors:  Doua Bakry; Melyssa Aronson; Carol Durno; Hala Rimawi; Roula Farah; Qasim Kholaif Alharbi; Musa Alharbi; Ashraf Shamvil; Shay Ben-Shachar; Matthew Mistry; Shlomi Constantini; Rina Dvir; Ibrahim Qaddoumi; Steven Gallinger; Jordan Lerner-Ellis; Aaron Pollett; Derek Stephens; Steve Kelies; Elizabeth Chao; David Malkin; Eric Bouffet; Cynthia Hawkins; Uri Tabori
Journal:  Eur J Cancer       Date:  2014-01-15       Impact factor: 9.162

3.  Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial.

Authors:  Nancy R Cook; I-Min Lee; Shumin M Zhang; M Vinayaga Moorthy; Julie E Buring
Journal:  Ann Intern Med       Date:  2013-07-16       Impact factor: 25.391

Review 4.  Aspirin and cancer risk: a quantitative review to 2011.

Authors:  C Bosetti; V Rosato; S Gallus; J Cuzick; C La Vecchia
Journal:  Ann Oncol       Date:  2012-04-19       Impact factor: 32.976

5.  Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium "Care for CMMR-D" (C4CMMR-D).

Authors:  H F A Vasen; Z Ghorbanoghli; F Bourdeaut; O Cabaret; O Caron; A Duval; N Entz-Werle; Y Goldberg; D Ilencikova; C P Kratz; N Lavoine; J Loeffen; F H Menko; M Muleris; G Sebille; C Colas; B Burkhardt; L Brugieres; K Wimmer
Journal:  J Med Genet       Date:  2014-02-20       Impact factor: 6.318

Review 6.  Aspirin and Cancer.

Authors:  Paola Patrignani; Carlo Patrono
Journal:  J Am Coll Cardiol       Date:  2016-08-30       Impact factor: 24.094

7.  Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells.

Authors:  Michael A McIlhatton; Jessica Tyler; Susan Burkholder; Josef Ruschoff; Basil Rigas; Levy Kopelovich; Richard Fishel
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

Review 8.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.

Authors:  Jack Cuzick; Florian Otto; John A Baron; Powel H Brown; John Burn; Peter Greenwald; Janusz Jankowski; Carlo La Vecchia; Frank Meyskens; Hans Jörg Senn; Michael Thun
Journal:  Lancet Oncol       Date:  2009-05       Impact factor: 41.316

9.  Chemoprevention in Lynch syndrome.

Authors:  John Burn; John C Mathers; D Tim Bishop
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

10.  Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.

Authors:  Santiago Zelenay; Annemarthe G van der Veen; Jan P Böttcher; Kathryn J Snelgrove; Neil Rogers; Sophie E Acton; Probir Chakravarty; Maria Romina Girotti; Richard Marais; Sergio A Quezada; Erik Sahai; Caetano Reis e Sousa
Journal:  Cell       Date:  2015-09-03       Impact factor: 41.582

View more
  7 in total

Review 1.  Cancer predisposition in pediatric neuro-oncology-practical approaches and ethical considerations.

Authors:  Steffen Hirsch; Nicola Dikow; Stefan M Pfister; Kristian W Pajtler
Journal:  Neurooncol Pract       Date:  2021-05-28

2.  An evolutionary explanation for antibiotics' association with increased colon cancer risk.

Authors:  Konstantinos Voskarides
Journal:  Evol Med Public Health       Date:  2022-04-29

3.  Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium.

Authors:  Léa Guerrini-Rousseau; Pascale Varlet; Chrystelle Colas; Felipe Andreiuolo; Franck Bourdeaut; Karin Dahan; Christine Devalck; Cécile Faure-Conter; Maurizio Genuardi; Yael Goldberg; Michaela Kuhlen; Salma Moalla; Enrico Opocher; Vanessa Perez-Alonso; Astrid Sehested; Irene Slavc; Sheila Unger; Katharina Wimmer; Jacques Grill; Laurence Brugières
Journal:  Neurooncol Adv       Date:  2019-12-02

4.  A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytes.

Authors:  Richard Gallon; Barbara Mühlegger; Sören-Sebastian Wenzel; Harsh Sheth; Christine Hayes; Stefan Aretz; Karin Dahan; William Foulkes; Christian P Kratz; Tim Ripperger; Amedeo A Azizi; Hagit Baris Feldman; Anne-Laure Chong; Ugur Demirsoy; Benoît Florkin; Thomas Imschweiler; Danuta Januszkiewicz-Lewandowska; Stephan Lobitz; Michaela Nathrath; Hans-Jürgen Pander; Vanesa Perez-Alonso; Claudia Perne; Iman Ragab; Thorsten Rosenbaum; Daniel Rueda; Markus G Seidel; Manon Suerink; Julia Taeubner; Stefanie-Yvonne Zimmermann; Johannes Zschocke; Gillian M Borthwick; John Burn; Michael S Jackson; Mauro Santibanez-Koref; Katharina Wimmer
Journal:  Hum Mutat       Date:  2019-03-06       Impact factor: 4.878

Review 5.  Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies.

Authors:  Malak Abedalthagafi
Journal:  Oncotarget       Date:  2018-10-23

Review 6.  Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome.

Authors:  Asima Abidi; Mark A J Gorris; Evan Brennan; Marjolijn C J Jongmans; Dilys D Weijers; Roland P Kuiper; Richarda M de Voer; Nicoline Hoogerbrugge; Gerty Schreibelt; I Jolanda M de Vries
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

7.  Diagnostic challenges in a CMMRD patient with a novel mutation in the PMS2 gene: a case report.

Authors:  Shiqing Tan; Xiaoting Wu; Aoxue Wang; Li Ying
Journal:  BMC Med Genomics       Date:  2021-07-12       Impact factor: 3.063

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.